Report of Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
Similar Posts
IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older
The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported globally. This is a precautionary measure while the MHRA conducts a safety review. The IXCHIQ vaccine will be available on the UK market from 18 June 2025.
Access Generic Medicines Work Sharing Initiative
This is a work sharing model for the co-ordinated assessment of a generic application that has been filed with multiple Access Consortium agencies.
Field Safety Notices: 23-27 February 2026
List of Field Safety Notices from 23-27 February 2026.
Updated guidance on the management of the recalled Endologix Nellix EndoVascular Aneurysm Sealing (EVAS) System (DSI/2025/004)
The MHRA provides an update to previous guidance on the management of patients treated with the recalled Endologix Nellix EVAS System to reflect revised recommendations. All implanted patients in the UK with this device should be identified and appropriate action taken.
Decision: Human and veterinary medicines: register of licensed manufacturing sites
The MHRA register of licensed manufacturing sites: manufacturer specials – human (MS) and manufacturer specials authorisation – veterinary (MANSA) only.
Medicines: apply for a parallel import licence
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.